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in the young age group. The ratio of dose reduction of the ﬁrst-cycle in 
initial chemotherapy were 14.8% in the young age group and 55.9% in 
the old age group(p<0.001). Despite lower dose-intensity of chemother-
apy, median overall survival of the old age group was similar to that of 
the young age group(12.6 vs. 13.9 months, p=0.3471). Among the old 
age group, the average of number of regimens(2.22 of elderly patients 
without comorbidity vs. 2.39 of those with comorbidity, respectively; 
p=0.454) and cycles(8.04 vs. 9.84, p=0.105) per head were similar 
between elderly patients without comorbidity and with comorbidity. 
There was no signiﬁcant difference in median overall survival between 
elderly patients without comorbidity and with comorbidity(11.2 vs 14.8 
months, p=0.3054). Elderly patients with dose-reduction of the ﬁrst-
cycle in the initial chemotherapy received signiﬁcantly less number of 
regimens(2.09 of elderly patients with dose-reduction vs. 2.62 of those 
without dose-reduction, p=0.017) and cycles of chemotherapy(7.79 vs. 
10.58, p=0.016) as compared with elderly patients without dose-reduc-
tion. Although elderly patients with dose-reduction received less num-
ber of regimens and cycles of chemotherapy, median overall survival 
of elderly patients with dose-reduction was equivalent to that of elderly 
patients without dose-reduction(11.2 vs. 14.8 months, p=0.0742).
Conclusions: Although signiﬁcantly lower dose-intensity of chemo-
therapies were conducted in elderly patients with advanced or recurrent 
NSCLC, the efﬁcacy and survival of elderly patients were similar to 
those of young patients. The optimal dose and schedule of palliative 
chemotherapy for elderly patients with advanced or recurrent NSCLC 
should be redeﬁned.
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Background: During anti-cancer chemotherapy for lung cancer and 
other various malignancies, some patients suffer due to sudden onset of 
dyspnea and acute respiratory failure with acute lung injury, diagnosed 
by chest CT and clinical ﬁndings. It is difﬁcult to make an immediate 
differential diagnosis of chemotherapy induced acute lung injury and 
other causes of acute lung injury, such as respiratory infection or sepsis.
Methods: We analyzed the clinical and laboratory characteristics, 
causative chemotherapeutic drugs, treatment responses of suspicious 
chemotherapeutic drug induced acute lung injury retrospectively.
Results: Fourteen patients with lung cancer and two cases of other 
cancer (esophageal and breast cancer) were included. The probable 
causative chemotherapeutic drugs were geﬁtinib (5 cases), docetaxel 
(5 cases), paclitaxel (1 case), navelbine (2 cases), gemcitabine (1 case), 
epirubicin (1 case), and etoposide (1 case). The most frequent radio-
lographic ﬁnding was ground glass attenuation detected in chest CT. 
Most of the patents were treated with broad spectrum antibiotics and 
steroid (methylprednisolone 125-250mg bid intravenously for 2-5 days 
or prednisolone 0.5-1mg/kg/day for 1-2 weeks) and mechanical ventila-
tion if needed. Twelve patients were survived, but 3 patients died due 
to reparatory failure and accompanied complications. The APACHE II 
score was high in non-survivors (23) compared to survivors (14.5). The 
patients with combined respiratory infection conﬁrmed by microbio-
logical studies showed unfavorable treatment response. The patients 
with more severe initial respiratory dysfunction requiring mechanical 
ventilatory supports showed poor prognosis.
Conclusion: It is important to make an early diagnosis and early 
initiation of treatment for acute lung injury associated with anti-cancer 
chemotherapy.
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Background: RRM1 is related to the resistance for gemcitabine che-
motherapy in patients who revealed high RRM1 expression in tumor 
tissues. This study was designed under the hypothesis that the poly-
morphism in RRM1 promoter, which regulate RRM1 gene expression, 
could impact on the result of the therapeutic response and the prognosis 
of the patients with lung cancer treated with gemcitabine.
Methods: A retrospective data set of 97 patients with advanced 
NSCLC treated with gemcitabine as the ﬁrst-line chemotherapy was 
studied. Allelotyping of RRM1 gene was performed with real-time 
PCR and sequencing using genomic DNA achieved from peripheral 
white blood cells.
Results: The frequencies of RRM1 gene promoter allelotypes were 
RR37CC-R524TT in 58, RR37AC-RR524CT in 29, and others in 
10. The response rate for gemcitabine containing chemotherapy was 
49.5%. When the author analyzed the therapeutic responses according 
to RRM1 promoter allelotypes, 65.5% in RR37AC-RR524CT group 
and 43.1% in RR37CC-RR524TT group (P = 0.049). There were no 
statistically signiﬁcant differences in overall survival and progression 
free survival by the two allelotypes. 
Conclusions: The response rate was higher in the patients’ group 
with RR37AC-RR524CT in which we expected to show lower level 
of RRM1 gene expression than in the patients’ group with RR37CC-
RR524TT, and that result was thought to correspond to our hypothesis. 
If further studies would verify and supplement the result of our study, 
we can expect to improve the prognosis of the advanced non-small cell 
lung cancer through the application of our result for the patient-tailored 
therapy.
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